Overview

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)
Phase:
Phase 2
Details
Lead Sponsor:
XenoPort, Inc.
Treatments:
Gabapentin
gamma-Aminobutyric Acid
Pregabalin